Drug Trial Radar · NCT06944379
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 19, 2025
Primary completion
Aug 20, 2026
Study completion Aug 20, 2026
Sponsor
- Lead sponsor
- Oruka Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.
Conditions
- Healthy Volunteers
Interventions
ORKA-002Drug
ORKA-002 is supplied as sterile solution to be administered by SC injection
PlaceboOther
Placebo solution to be administered at a matching volume by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse EventsTime frame: Day 1 through 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Oruka Therapeutics Investigative Site
Christchurch, New Zealand, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.